OR WAIT null SECS
© 2023 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 2, 2021.
The US Food and Drug Administration (FDA) has delayed its decision on upadacitinib (RINVOQ) for the for the treatment of adults with active psoriatic arthritis and adults with active ankylosing spondylitis.
Click the image to view the story.
Rheumatology Network sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.
Click the image to view the story.
Test your knowledge of the treatment and management of rheumatoid arthritis (RA) with our RA quizzes.
Click the image to view the story.
Eric Morand, MD, PhD, explains why rheumatologists failing in lupus while succeeding so spectacularly in diseases like rheumatoid arthritis and what needs to change.
Click the image to view the story.
In patients with early inflammatory arthritis, a serum protein biomarker panel was proven effective in separating patients with psoriatic arthritis from those with rheumatoid arthritis.
Click the image to view the story.